CDK1 and cancer: CDK1 upregulation has been associated with intra-tumoral immune alterations in a variety of human cancers, including high levels of expression of lymphocytes negatively regulating antitumor immunity [23], as well as Wnt/β-catenin activation [24,25,26], known to diminish STING activation followed by reduced priming of antitumor T cell immune responses.